Answers are grounded in this paper and cite their sources.
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, severe, antibody-mediated autoimmune disorder of the central nervous system. Interleukin-40 (IL-40), a novel B-cell–associated cytokine, has been implicated in various autoimmune diseases; however, its levels have not been investigated in patients with NMOSD. In this exploratory case–control study, 32 patients who were diagnosed with NMOSD during acute attacks and 30 age- and sex-matched healthy controls (HCs) were enrolled. Using an enzyme-linked immunosorbent assay (ELISA), serum IL-40 levels were measured both before and after acute high-dose intravenous methylprednisolone treatment. Comprehensive clinical data were systematically collected from all participants. Between-group differences were assessed using non-parametric tests, and receiver operating characteristic (ROC) curve analysis was used to explore the ability of serum IL-40 levels to discriminate patients with NMOSD from HCs. Serum IL-40 levels were significantly higher in patients with NMOSD than in HCs (median 2.64 vs. 0.89 ng/mL; p < 0.001). IL-40 levels tended to be higher in AQP4-IgG–seropositive patients (n = 22) than in seronegative patients (n = 10), but the difference was not statistically significant ( p = 0.070). In patients with NMOSD, serum IL-40 levels were significantly lower after acute corticosteroid treatment than before treatment, and this decrease was observed in all 32 patients ( p < 0.001). ROC curve analysis showed that serum IL-40 levels discriminated patients with NMOSD from HCs, with an area under the curve (AUC) of 0.917 (95% confidence interval [CI] 0.844–0.990; p < 0.001). Moreover, serum IL-40 levels were positively correlated with Expanded Disability Status Scale (EDSS) scores during the acute phase ( r = 0.798, 95% CI 0.622–0.897; p < 0.001). Serum IL-40 levels were elevated in patients with NMOSD during acute attacks, correlated positively with acute-phase neurological disability, and decreased following acute corticosteroid treatment. These exploratory findings suggest that IL-40 is a candidate biomarker of disease activity in NMOSD, warranting validation against disease controls and further mechanistic studies.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: